Blockbuster prescription drugs sold worldwide that treat multiple sclerosis, cancer, Alzheimer’s and Parkinson’s diseases derive from Israeli biotechnology.
Israel creates more medical devices per capita than any other country, and its life sciences exports earn more than $3 billion a year.
Israeli research is at the forefront of the emerging fields of stem-cell therapy and genomics, and two Nobel Prizes in Chemistry, the first to Profs. Avram Hershko and Aaron Ciechanover of the Technion-Israel Institute of Technology, and the second to Prof. Ada Yonath of the Weizmann Institute of Science number among the many awards bestowed on the country’s biotech scientists.
The pace of innovation, development and growth in Israel’s biotechnology sector is unparalleled in the world, with more startups per capita than any other country.
Its 180 biotech companies – each built on a combination of academic excellence, a highly-skilled workforce, cutting-edge technological inventiveness and entrepreneurial daring – are creating therapeutic products, diagnostic tools and revolutionary drug-delivery techniques benefiting people all over the world.
Biotechnology, the science which applies breakthroughs in molecular biology and immunochemistry to diagnosis and therapy, was born in the late 1970s.
In many ways, it is tailor-made for Israel, being rooted in innovation and perseverance, a highly educated workforce, the lessons of military service, intimate links between researchers and entrepreneurs.